Nineteen people with T1D (10 male, 9 female. Age: 31 +/- 9 yrs, A1c: 6.6 +/- 0.8 and duration of diabetes: 19 +/- 11 years) had their sleep monitored with an EEG-based device (Zmachine Insight+) for a total of 154 nights. Their blood glucose levels (BGL) were measured with a CGM. From the CGM data, the participant’s average BGL, standard deviation of BGL, coefficient of variation of BGL, Percent Time in Range (70-180 mg/dL), Percent Time Above Range (>180 mg/dL), and Percent Time Below Range (<70 mg/dL) was calculated for each overnight period. A t-Test was used to determine if there was a difference between characteristics in the participants’ overnight BGL based on different sleep quality metrics. Participants who had sleep efficiency scores > 85% had less variable overnight BGL determined by the standard deviation and coefficient of variation of CGM (p = 0.0013 and 0.017). Participants who had higher average overnight BGL and more fluctuations, as determined by standard deviation and coefficient of variation, in their BGL (p = 0.017, 0.000004, and 0.0004) spent more time awake overnight. Those who have lower average overnight BGL spent more time in Deep and REM sleep stages (p = 0.044 and 0.0043). From these findings, we can conclude that overnight BGL has a significant impact on sleep quality in people with T1D. Based on previous research, this reduction in sleep quality may negatively impact daytime control.


R. Brandt: None. M. Park: None. L.T. Quinn: None. M. Chu: None. Y. Song: None. B.M. Burton-Freeman: None. A. Cinar: Research Support; Self; Dexcom, Inc., JDRF. Stock/Shareholder; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk A/S, Tandem Diabetes Care.


JDRF (A18-0036-001)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at